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ABSTRACT
Objectives To describe the clinical presentation and
sequelae, including salt-wasting crises of newly-
diagnosed congenital adrenal hyperplasia (CAH) in
children aged over 1 year in a contemporary population
without screening. To appraise the potential beneﬁt of
newborn screening for late-presenting CAH.
Design Active national surveillance undertaken in Great
Britain prospectively from 2007–2009 through the
British Paediatric Surveillance Unit.
Setting England, Wales and Scotland.
Patients Children ﬁrst presenting aged 1–15 years
with clinical features of CAH and elevated
17-hydroxyprogesterone.
Results Fifty-eight children (26 [45%] boys) aged
1–15 years were reported; 50 (86%) had 21-hydroxylase
deﬁciency. Diagnosis was precipitated by secondary
sexual characteristics (n=38 [66%]; median age 5.8
[IQR] 4.8, 7.6) years, genital virilisation (8 girls; 3.2 [IQR
1.3, 7.3] years) or an affected sibling (n=8; 10.0 [IQR
7.4, 13.3] years). At least 33 (57%) children had
advanced bone age and 13 (30%) were obese (body
mass index ≥95th centile). No child had experienced a
salt-wasting crisis.
Conclusions In Great Britain, 30 children aged
1–15 years present annually for the ﬁrst time with CAH.
Older children frequently manifest prematurely advanced
epiphyseal and pubertal maturation and genital
virilisation, which are often irreversible and likely to have
long-lasting consequences for adult health and
wellbeing. Almost one-third of affected children are
obese before commencing steroid therapy. Newborn
screening offers the potential to avoid serious clinical
manifestations in older children with unrecognised CAH;
however, it may also detect some children who would
otherwise remain asymptomatic and for whom the
beneﬁt from treatment is uncertain.
INTRODUCTION
Congenital adrenal hyperplasia (CAH) refers to a
group of recessively inherited enzyme deﬁciencies
inﬂuencing adrenal steroid production, leading to
decreased cortisol and aldosterone and excessive
androgens.1 It affects approximately one in 18 000
liveborn infants in the UK, but not all cases are
diagnosed within the ﬁrst year of life.2 Newborn
screening for CAH is not currently undertaken in
the UK although this is under review by the
National Screening Committee.2
Three forms of CAH are often described: clas-
sical CAH comprises salt-wasting (SW) and simple
virilising (SV) forms, while a late-onset form is fre-
quently termed non-classical (NC). In newborns,
SW-CAH can lead to life-threatening crises due to
the inability to maintain sodium balance, while
SV-CAH often manifests as female genital virilisa-
tion. Key presenting features in older children
include premature pubarche and accelerated early
growth leading to premature epiphyseal maturation
and adult short stature.3 4 Recently, concern has
also been raised about obesity.5 6 If untreated,
excess androgen production stimulates progressive
virilisation, premature pubic hair development,
girls may not develop regular menses and infertility
is possible in both sexes.1 Research into the psycho-
social impact has hitherto primarily concerned the
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What is already known on this topic
▸ Congenital adrenal hyperplasia (CAH)
presenting in older children is often considered
‘late-onset’ or ‘non-classical’, but may also be
due to delayed recognition of simple-virilising
or salt-wasting forms.
▸ If CAH remains untreated due to delayed
recognition, excess androgen production can
stimulate progressive virilisation, premature
epiphyseal and sexual maturation and lead to
infertility.
▸ CAH is a lifelong, chronic condition and
reduced quality of life has been demonstrated
in affected adults in the UK.
What this study adds
▸ Each year in Great Britain, in an unscreened
population, around 30 children aged over
1 year are clinically diagnosed with congenital
adrenal hyperplasia.
▸ Two-thirds of children presented at primary
school age with premature secondary sexual
characteristics, 57% children had advanced
bone age and 25% girls presented with
virilisation.
▸ Newborn screening could potentially avert the
signiﬁcant late impacts on health and quality
of life, in addition to reducing neonatal
mortality and adrenal crises.
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masculinising effects of excess androgen on the female brain;7
however, reduced quality of life has been demonstrated for
adults with CAH.8 Although steroid replacement therapy should
avert adrenal crises and facilitate normal development, CAH has
a lifelong impact on health.9
While the epidemiology of infants is well-described,2 10 11
fewer reports exist of clinical presentation with CAH in older
children3 in whom life-threatening episodes are rare but who
nonetheless experience avoidable adverse sequelae. We used
data collected through the British Paediatric Surveillance Unit
(BPSU), which obtained over a 2-year period, notiﬁcations of all
new CAH diagnoses in children aged 15 years and under resi-
dent in Great Britain. Speciﬁcally, we estimated the incidence of
late clinical presentation and its associated complications.
METHODS
Active surveillance for CAH in children aged 0–15 years in
Great Britain was undertaken prospectively from 2007 to 2009
through the BPSU, a national paediatric rare disease surveillance
system involving almost all UK consultant paediatricians
(n=3000). Every month paediatricians return a postal Orange
card, listing approximately 10 conditions under surveillance,
stating the number of children diagnosed with each condition in
the previous month or indicating ‘no cases to report’. As
described in our earlier paper,2 cases of CAH were deﬁned by
speciﬁed clinical features in association with elevated plasma
17-hydroxyprogesterone (17-OHP). Clinicians reporting a case
subsequently completed a detailed questionnaire using each
child’s hospital case notes. In accordance with BPSU surveillance
methodology, clinicians were not asked to arrange additional
clinic visits or to perform any additional tests or examinations.
Findings from diagnostic investigations, such as 17OHP, urinary
steroids, DNA and synacthen stimulation were reported by clini-
cians against local age-standardised reference norms. As there
was considerable variation in the tests performed and reference
standards used in local clinical practice, all completed question-
naires were reviewed centrally by an expert panel of clinicians
who determined whether a child had CAH or not on the basis
of the clinical presentation and investigations reported by local
clinicians.
Age-speciﬁc incidence of diagnosis was calculated, excluding
children notiﬁed in the ﬁrst reporting month to ensure that
prevalent cases were not included. Height and weight z-scores
were standardised for age and sex against the British 1990
growth reference.12 Analyses were performed using Stata SE
V.11 (StataCorp, College Station, Texas, USA).
Ethical approvals were obtained (ref: 07/MRE12/25; PIAG/
BPSU 1-05(FT4)/2007).
RESULTS
During 25 months of surveillance, 144 children with new diag-
noses of CAH were identiﬁed by clinicians working at 53 insti-
tutions. The monthly BPSU card return rate was 92%–94% and
the questionnaire completion rate for CAH case reports was
95%. As described previously,2 86 children (36 boys) presented
within the ﬁrst year of life (genital virilisation=37; SW
crisis=30, affected sibling=12, other=8). Of 60 children pre-
senting after age 1 year, two with precocious puberty were
determined not to have CAH after expert panel review. In this
paper, we describe 58 children who presented clinically with
CAH aged 1–15 years (median age 5.9 [IQR 4.7, 8.4] years;
table 1).
Table 1 Characteristics of children with late-presenting CAH (n=58)
Characteristics
All children Male Median age
Interquartile range (IQR)n (% of 58) n Years
All children 58 – 5.9 4.7, 8.4
Subtype
21-hydroxylase deficiency 50 86 21 5.6 4.2, 7.8
11β-hydroxylase deficiency 6 10 <5 9.1 6.4, 13.9
Sex
Boys (M) 26 45 – 5.4 4.2, 8.1
Girls (F) 32 55 – 6.4 4.7, 8.4
Ethnicity
White 40 69 18 5.5 4.5, 7.6
Asian/British Asian* 12 21 6 7.7 3.1, 13.3
Other 6 10 <5 7.4 6.3, 10.1
Clinical features at first presentation
Secondary sexual characteristics† 38 66 20 5.8 4.8, 7.6
Female genital virilisation 8 14 0 3.2 1.3, 7.3
Affected sibling‡ 8 14 <5 10.0 7.4, 13.3
Genetic mutations
No genetic testing undertaken§ 27 46 13 7.3 5.4, 9.6
Genetic testing—results not provided 15 26 <5 6.3 4.2, 9.0
Genetic testing—results available 16 28 9 4.7 3.3, 5.4
Note: To avoid disclosure cells with n<5 have not been included; not all sections include 58 individuals.
Numbers in italics in the IQR column are the 25th and 75th centile.
*Asian/British Asian denotes Indian, Pakistani or Bangladeshi ethnic origin (UK Census 2001).
†These were also described by some clinicians as ‘precocious puberty’.
‡Features at presentation included advanced bone age, secondary sexual characteristics, adrenal insufficiency, virilisation and hypertension; more than one feature was noted in some
individuals.
§Children in whom genotyping was not requested were older than those genotyped (Mann–Whitney p=0.04). Clinicians were unable to provide DNA results in 16 cases.
CAH, congenital adrenal hyperplasia.
Knowles RL, et al. Arch Dis Child 2014;99:30–34. doi:10.1136/archdischild-2012-303070 31
Original article
The annual age-speciﬁc incidence (risk) of CAH diagnosis
between 1 and 15 years of age (based on 52 children notiﬁed
between 1 September 2007 and 31August 2009) was 0.23 per
100 000 children (Fisher’s exact 95% CIs 0.19 to 0.33) and did
not differ by sex (data not shown).
Boys comprised 45% of those with late-presenting CAH
(n=26; 95% CI 32% to 58%). Median age at ﬁrst clinical pres-
entation was similar for both sexes (table 1; Mann–Whitney
p=0.40). The most frequently encountered subtypes were
21-hydroxylase and 11β-hydroxylase deﬁciency (table 1). Forty
children (69%) were white British and 12 (21%) were Asian/
British Asian ethnicity.
Diagnosis was most frequently precipitated by presentation
with secondary sexual characteristics (table 1), which occurred
at a median age of 5.8 (IQR 4.8, 7.6) years. Four additional
children, investigated after diagnosis of CAH in a sibling also
demonstrated secondary sexual characteristics. Eight girls ﬁrst
presented with virilisation: six at Prader stage 1and two at stage
3 or 4. Nine girls who presented due to secondary sexual char-
acteristics or an affected sibling were also virilised (Prader 1
or 2). Of eight children investigated only after a sibling was
diagnosed, six had clinical signs (table 1). No child experienced
adrenal crisis, deﬁned as a life-threatening state of cardiovascu-
lar collapse; however, ﬁve children manifested adrenal insufﬁ-
ciency (biochemical changes indicating inadequate cortisol
production) at ﬁrst presentation and, in one additional child,
this developed subsequently. Median interval from initial suspi-
cion to conﬁrmation of CAH was 33 days (IQR 14, 59 days;
n=51) and did not differ by sex or ethnicity (data not shown).
Median 17-OHP concentration reported for 50 (86%) chil-
dren at presentation without synacthen stimulation was 95 (IQR
25, 208) nmol/L. Subsequent diagnostic investigation varied; 32
children had a synacthen stimulation test, reported as ‘abnormal’
in all cases and 40 children had urinary steroid proﬁling which
was diagnostic in 38 cases. DNA results were available for 16
children (table 1; DNA results unavailable=15). The most fre-
quently observed mutations were g.999T>A (9 children),
g.655A/C>G (5 children) and g.1683G>T (4 children).
At notiﬁcation, 48 (83%) children had commenced gluco-
corticoid, and seven, mineralocorticoid replacement therapy.
Almost 90% (n=52) were referred to another specialist, usually
a paediatric endocrinologist (n=42) or geneticist (n=21).
Although 32 children were reported to have ‘accelerated
growth’, this precipitated diagnosis in only two; however,
routine growth monitoring in England is undertaken only at
ages 5 and 11 years.13 Bone age was assessed in 36 (63%) chil-
dren and was advanced in 33, appropriate in two and retarded
in one relative to chronological age (magnitude not reported).
Height, weight and body mass index (BMI) SD scores (SDS)
at diagnosis were estimated for 44 children (ﬁgure 1). Height
SDS was >2.0SD in 39% (17/44) children, all diagnosed aged
under 11 years, but <1.0SD in all four children diagnosed after
11 years. Weight SDS was >2.0SD in 41% (18/44) children and
did not show any clear pattern with age. BMI ranged from 14
to 37; 13 (30%; 4 boys; 9 girls) were obese (BMI ≥95th
centile13).
DISCUSSION
We report the incidence and clinical features of new diagnoses
of CAH in children aged over 1 year in Great Britain ascertained
through active national surveillance of over 3000 paediatricians
with a 94% monthly response rate. We estimate 30 children
aged 1–15 years are diagnosed annually with CAH with over-
representation of children of Asian ethnic origin.14 The age-
speciﬁc risk of new CAH diagnosis aged 1–15 years is low at
0.23 per 100 000 in comparison with 5.5 per 100 000 children
aged under 1 year,2 suggesting that most affected children are
diagnosed during infancy.
Diagnosis in three-quarters of children was precipitated by
premature secondary sexual characteristics at a median age of
6 years. At diagnosis, 50% of girls had virilised genitalia and at
least half of all children had advanced bone age. Although one
in seven children were investigated only after their sibling had
been diagnosed, most had signs of CAH when examined.
Premature pubarche, genital virilisation and advanced bone age
are largely irreversible and have long-lasting implications for
health. While the rationale for early detection is primarily pre-
vention of SW crises, newborn screening also offers the poten-
tial to avoid serious clinical manifestations of CAH in older
children.
Major strengths of this study were the high case ascertain-
ment and questionnaire completion rate due to active surveil-
lance. Nevertheless, it is possible that some affected children
were not reported by clinicians or remain undiagnosed, particu-
larly those with mild or asymptomatic CAH, resulting in a bias
Figure 1 SD scores (SDS) for height and weight at ﬁrst presentation
with congenital adrenal hyperplasia for children over 1 year of age
(n=44). (A) Height SDS. (B) Weight SDS. (C) Body mass index (BMI) SDS.
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towards reporting more severe cases. Laboratory surveillance
did not have coverage of the whole UK and was not fully inde-
pendent. So, we were unable to perform capture-recapture15
analyses to estimate completeness of ascertainment. As we were
restricted to requesting information available from case notes,
some analyses, such as gene mutations were limited by clinical
practice and small sample sizes. NC-CAH phenotype has been
associated with g.1683G>T and g.89C>T gene mutations,
which were the least severe mutations found in six study chil-
dren. In eight further children in our sample, the least severe
mutation was g.999T>A and in two children the mutation was
g.655A/C>G; these have been associated with SV-CAH and
SW-CAH phenotypes respectively.16 Speiser has suggested that
the penetrance of genes for NC-CAH varies between
populations.17
Previous population-based paediatric surveillance studies in
Australia10 and the Netherlands,11 report little detail of postin-
fant diagnoses. Thilen’s3 retrospective case series from Sweden
provide data from an unscreened population during 1969–1986
and included 29 children presenting between 1 and 14 years of
age; median age at diagnosis was 4 years and median delay in
conﬁrming the diagnosis was 17 months after initial symptoms.
Children diagnosed after 1 year old had bone ages advanced by a
mean 55 months and ﬁnal height for most was 1.0SD below the
population mean. Eugster4 demonstrated that children treated
appropriately for CAH achieved a ﬁnal height within 1.0SD of
the mid-parental prediction and emphasised that diagnosis
within the ﬁrst year of life was a crucial factor. Nevertheless
Nordenstrom has cautioned that, with the advent of newborn
screening in Sweden, some children with mild disease may be
receiving excess steroid replacement therapy and experiencing a
detrimental effect on growth.18 Our data from an untreated
population of children with CAH are consistent with previous
ﬁndings of accelerated epiphyseal maturation leading to short
stature. Although children diagnosed after age 11 years within
our study had reduced height z-scores, we did not collect longitu-
dinal data or parental heights, so cannot draw conclusions about
target height or individual growth trajectories.
Glucocorticoid therapy does not provide physiological steroid
replacement and an association with obesity, hypertension and
metabolic syndrome in children with CAH has been proposed;
there is also increasing evidence that CAH-related obesity places
affected adults at higher risk of cardiovascular complications.5 6 9
In our study, we found that 21% boys and 41% girls aged
1–15 years were obese at the time of ﬁrst diagnosis and prior to
commencing steroid replacement therapy; this compares with
10% boys and 9% girls aged 5 years, and 20% boys and 17%
girls aged 11 years in England whose BMI ≥95th centile during
an equivalent time period.13 Our ﬁndings of obesity in an
untreated population of children and adolescents with CAH
support earlier studies reporting a higher risk of obesity in indi-
viduals with CAH.5 6 9 Previous authors have proposed that the
causes of obesity in children and adults with CAH are multifac-
torial and our study provides additional evidence that the
disease process inﬂuences weight gain independently of gluco-
corticoid therapy.
Our prospective population-based study has high ascertain-
ment of clinically diagnosed cases within an unscreened popula-
tion. Some authors19 have concluded that increased clinical
awareness has reduced adverse neonatal outcomes and ques-
tioned the need for newborn screening, while Grosse20 has sug-
gested that deaths with undiagnosed CAH are lower than
previously estimated. Screening is usually advocated on the basis
of averting neonatal crises; measuring the burden of disease in
older children, who in our study already had evidence of genital
virilisation, secondary sexual characteristics, accelerated growth
and/or obesity at diagnosis, is highly relevant to understanding
whether newborn screening would have additional beneﬁt in
preventing adverse outcomes in children who represent
late-onset or perhaps ‘missed’ mild cases of CAH. Screening
based on biochemical or genetic markers in the newborn blood-
spot should be approached with caution, however, as it might
also detect children with CAH who would otherwise remain
asymptomatic. For these children, the beneﬁt from treatment is
uncertain, particularly in view of the potential negative effects
of glucocorticoid therapy highlighted by Nordenstrom.18 Our
data suggest that some children with previously unrecognised
CAH do seek treatment for clinical manifestations of the condi-
tion during later childhood and earlier detection would increase
the potential for improving therapy and interventions to opti-
mise their ﬁnal height and weight. Nevertheless, the impact on
mild or asymptomatic CAH should remain a key consideration
when determining the implications of introducing a newborn
screening programme.
Late childhood diagnosis of CAH has signiﬁcant implications
for adult health and early detection and treatment might
prevent adverse clinical progression and irreversible sequelae.
Carroll estimated the beneﬁt of newborn screening for CAH at
$20 357 per quality adjusted life-year gained.21 The anticipated
beneﬁts of newborn screening for CAH should not therefore be
conﬁned to preventing mortality and serious neurological mor-
bidity due to neonatal adrenal crises, but should also include the
potential to avert any signiﬁcant late impacts on adult health
and quality of life.
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